IL-23 Blocker for Psoriasis Successful in Extension Trials

For those with chronic plaque psoriasis, responses to tildrakizumab, an experimental interleukin-23 inhibitor, were upheld in two long-term extension studies, and FDA approval could be in the offing.
Medscape Medical News

http://ift.tt/2xOBWtk